Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
small interfering RNA targeting TBCE + cisplatin
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Small interfering RNA targeting TBCE + cisplatin is an experimental combination therapy designed to overcome platinum-based resistance in hepatocellular carcinoma (HCC). The formulation consists of endosomal pH-responsive nanoparticles that co-deliver a small interfering RNA (siRNA) against tubulin folding cofactor E (TBCE) and the DNA-alkylating agent cisplatin. TBCE is a chaperone protein essential for tubulin heterodimer formation and microtubule dynamics; its overexpression is associated with poor prognosis and chemoresistance in liver cancer. By silencing TBCE, the therapy disrupts the cytoskeleton, thereby enhancing the sensitivity of tumor cells to cisplatin-induced DNA damage, cell cycle arrest, and apoptosis. This synergistic approach has demonstrated efficacy in reversing drug resistance in both orthotopic and patient-derived xenograft (PDX) models of liver cancer.
- Other names
- siTBCE + cisplatinsiRNA targeting TBCE and cisplatin combination
02
Targets
TBCE (Tubulin-specific chaperone E)
Beyond the preview
Go deeper on small interfering RNA targeting TBCE + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on small interfering RNA targeting TBCE + cisplatin.